Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634058 | 0.80 | CDC25B (0.37) | LMNAMAPTHTTCYP2C9ALOX15 | |
| SCHEMBL5634034 | 0.79 | CDC25B (0.38) | LMNAMAPTHTTCYP2C9ALOX15 | |
| SCHEMBL5633433 | 0.79 | CDC25B (0.38) | LMNAMAPTHTTCYP2C9ALOX15 | |
| SCHEMBL5633728 | 0.76 | LMNA (0.49) | LMNAMAPTHTTCYP2C9ALOX15 | |
| SCHEMBL7284066 | 0.67 | ALDH1A1 (0.43) | LMNAMAPTHTT | |
| SCHEMBL5632794 | 0.63 | ALDH1A1 (0.43) | MAPTHSD17B10 | |
| SCHEMBL8822655 | 0.62 | ALDH1A1 (0.35) | LMNAMAPTHTTCYP2C9ALOX15 | |
| SCHEMBL5633265 | 0.60 | AGTR1 (0.40) | MAPT | |
| SCHEMBL12588788 | 0.60 | LMNA (0.53) | LMNAMAPTHTTCYP2C9ALOX15 | |
| SCHEMBL6233648 | 0.60 | LMNA (0.47) | LMNAMAPTHTTCYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123548-A1 | Pth agonists | COWAN DAVID J | 2007-05-31 | — | — | US | claimed |
| EP-1713782-A1 | PTH AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005077918-A1 | PTH AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20070123548-A1 | Pth agonists | COWAN DAVID J | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123548-A1 | Pth agonists | PTH1R, SSTR3, CALCR | LMNA 2409/4885MAPT 4835/4885HTT 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.